NORTH AMERICAN BUSINESS
  • HOME
  • SUSTAINABILITY
  • INVEST
  • MARKET
  • PARTNERSHIP
  • INNOVATION
  • PEOPLE
  • INSIGHTS
No Result
View All Result
NORTH AMERICAN BUSINESS
  • HOME
  • SUSTAINABILITY
  • INVEST
  • MARKET
  • PARTNERSHIP
  • INNOVATION
  • PEOPLE
  • INSIGHTS
No Result
View All Result
NORTH AMERICAN BUSINESS
No Result
View All Result
Home ALL Healthcare

Merck Completes New Viral Vector Contract Development Manufacturing Facility for Gene Therapy

by Emma Jones
October 13, 2021
A A
  • Expansion in Carlsbad, California, USA, doubles production capacity to support commercialization and industrialization of viral vectors
  • Investment serves customers in addressing larger patient populations with new curative treatments
  • Enables suspension production of viral vectors up to 1,000-liter scale
  • Project adds to company’s ambition to accelerate growth through investments in “Big 3” businesses, which includes plans to expand Process Solutions’ contract manufacturing and development organization (CDMO) services for traditional and novel modalities

Merck, a leading science and technology company, today announced the opening of its second Carlsbad, California-based facility, significantly expanding its global CDMO footprint. This new €100 million, 140,000-square foot facility will more than double the company’s existing capacity to support large-scale commercial and industrial manufacturing for viral gene therapy, in a market expected to grow to $10 billion by 2026.

“Today, most gene therapies target rare diseases, but there is an urgent need to efficiently manufacture these treatments to reach larger patient populations,” said Matthias Heinzel, Member of the Executive Board of Merck and CEO Life Science. “As a leader in viral vector manufacturing, this increase in capacity and scale is the next step in enabling our customers to bring new curative treatments to market.”

This is the company’s second Carlsbad, California-based facility to serve cell and gene therapy customers driven by the industry’s rapid adoption of viral vector-based therapies. Between the two facilities, there are 30 cleanroom suites to support all aspects of manufacturing from small- to large-scale clinical and commercial production. The new facility leverages cutting-edge suspension technology to enable scalable and cost-effective manufacturing.

“We are continuing to invest in solving cell and gene therapy challenges in development and manufacturing, working alongside drug developers to industrialize, scale and accelerate the path to deliver therapies to patients,” Heinzel added.

The expansion of the Carlsbad facility adds to the company’s ambition to accelerate growth through investments in the “Big 3”, including the Process Solutions business unit within the Life Science business sector as a key driver.

Merck has proven its commercial execution and global regulatory success as one of the first CDMOs to be granted U.S. Food and Drug Administration and European Medicines Agency approval for viral vector manufacturing. With nearly 30 years of experience in cell and gene therapy, Merck offers unique CDMO services streamlined as a single, highly experienced provider.

Tags: < Invest | M&A
ShareTweetShareSend

Related Industries

Healthcare

Thermo Fisher Scientific Releases 2022 Corporate Social Responsibility Report

May 18, 2023
Healthcare

Oncotelic Participating at 2023 BIO International Convention

May 17, 2023
Healthcare

Medtronic AccuRhythm AI technology receives 2023 MedTech Breakthrough Award as Best New Monitoring Solution

May 17, 2023
Healthcare

Amgen Responds to Ftc Action RE: Proposed Acquisition Of Horizon Therapeutics

May 17, 2023
Healthcare

Cardinal Health Canada to open new distribution center in Ontario

May 11, 2023
Healthcare

Thermo Fisher Scientific & Pfizer Partner to Expand Localized Access to Next Generation Sequencing-Based Testing for Cancer Patients in International Markets

May 10, 2023

Tesla Lithium Refinery Groundbreaking

May 9, 2023

...

Thermo Fisher Scientific & Pfizer Partner to Expand Localized Access to Next Generation Sequencing-Based Testing for Cancer Patients in International Markets

May 10, 2023

...

Dow and New Energy Blue to develop renewable plastic materials from corn residue.

Dow and New Energy Blue announce collaboration to develop renewable plastic materials from corn residue

May 26, 2023

...

PPG Board of Directors recognized as ‘Public Company Board of the Year’

May 13, 2023

...

Dow’s Seadrift, Texas location selected for X-energy advanced SMR nuclear project to deliver safe, reliable, zero carbon emissions power and steam production

May 12, 2023

...

GE Announces Chief Financial Officer Transition; Names Rahul Ghai Chief Financial Officer

May 19, 2023

...

Andrew Cornelia appointed to lead the new Mercedes-Benz charging network in North America – Christopher Trainor responsible for finance

June 1, 2023

...

MSC’s largest cruise ship, World Europa (World Class Series), is equipped with GE Power Conversion’s in-board propulsion system

May 12, 2023

...

chevron announces agreement to acquire PDC energy

May 23, 2023

...

NORTH AMERICAN BUSINESS (www.na-biz.com) is a leading source of business and corporate news, information, industry trends, market updates and insights across a broad spectrum of industries in North America and worldwide.

MENU

  • HOME
  • SUSTAINABILITY
  • INVEST
  • MARKET
  • PARTNERSHIP
  • INNOVATION
  • PEOPLE
  • INSIGHTS

CONTACT US

EDITORIAL:     editor#na-biz.com

PARTNERSHIP:     biz#na-biz.com

HUMAN RESOURCE:     hr#na-biz.com

* (replace # with @)

  • Official Site

Copyright © NA-BIZ.COM All rights reserved.

No Result
View All Result
  • HOME
  • SUSTAINABILITY
  • INVEST
  • MARKET
  • PARTNERSHIP
  • INNOVATION
  • PEOPLE
  • INSIGHTS

Copyright © NA-BIZ.COM All rights reserved.